Ischemia Reperfusion Injury pipeline Research Monitor, 2020- Drugs, Companies, Clinical Trials, R&D pipeline updates, status and outlook

July 2020 | 170 pages | ID: I97E0DC24DD0EN
VPAResearch

Abstracts

2020 Ischemia Reperfusion Injury PIPELINE HIGHLIGHTS
Ischemia Reperfusion Injury is one of the widely researched conditions during 2020 with 38 companies actively focusing on realizing pipeline’s potential. Development of Ischemia Reperfusion Injury medicines is identified as integral to the strategy of the majority of companies operating in the industry.
Global Ischemia Reperfusion Injury market presents promising new product pipeline with NME Projects, pivotal trials, and rapidly phase-advancing therapeutic candidates. Increasing number of companies are assessing the feasibility of developing treatment options for Ischemia Reperfusion Injury.

Good progress is anticipated during 2020 and 2021 with Ischemia Reperfusion Injury pipeline molecules advancing from pre-clinical investigation to completion of advanced Phase clinical trials. Ischemia Reperfusion Injury pipeline continues to expand and progress with novel mechanisms and diverse routes of administration being tested by companies.
Ischemia Reperfusion Injury DRUG DEVELOPMENT PIPELINE OVERVIEW
The “Ischemia Reperfusion Injury pipeline Research Monitor, 2020” report is an analytical research study on the progress achieved by pipeline companies during the year along with its historical development, current status, and outlook.
This Ischemia Reperfusion Injury pipeline review explores high-potential early to late-stage pipeline projects with a continued focus on new insights, accelerated processes, and pipeline progression.

The competitive intelligence report on Ischemia Reperfusion Injury presents detailed insights into therapeutic drug pipeline development, industry news, deals, and analysis across the length and breadth of the Ischemia Reperfusion Injury pipeline. Information on R&D pipeline updates, results of key clinical trials are also included in the report.
Ischemia Reperfusion Injury DRUG PROFILES
Ischemia Reperfusion Injury development pipeline including projects in early- and late-stage development are detailed in the report. Details of clinical trial data and submissions to regulatory authorities are also provided. For the drug candidates included in the report, the following information is provided-

• Current Status of Development including phase advancements, regulatory approvals of phases, acquisitions, licensing and technology transfers, product launches in various markets, and others.
• Phase of development
• Mechanism of Action
• Route of Administration
• Companies involved including originator, licensing companies, developer, investors, and others
• New molecular entity details
• Orphan drug designation and other special status provided by regulators

Ischemia Reperfusion Injury COMPANY PROFILES

Both small size and large size pharmaceutical companies are investing their resources in Ischemia Reperfusion Injury drug development operations. Further, financial institutions are extending support to small pharmaceutical companies, universities, and other researchers for the development of treatment of Ischemia Reperfusion Injury. Partnerships and acquisitions are also increasingly observed in the pipeline.

This research report presents an analysis of 38 Ischemia Reperfusion Injury companies including company overview, key snapshot, contact information, and their strategies on accelerating Ischemia Reperfusion Injury pipeline development. Mid-stage and early portfolios of these companies are analyzed in detail in the report.

Companies analyzed in the report include- Acelerox LLC, Affinicon ApS, Amyndas Pharmaceuticals LLC, Apollo Therapeutics LLC, Aptorum Group Ltd, Argenx SE, Armaron Bio Pty Ltd, Axolo Pharma Inc, Balmes Transplantation SAS, Bolder Biotechnology Inc, Catalyst Biosciences Inc, Celdara Medical LLC, Cellmid Ltd , CFM Pharma Holding BV, Corline Biomedical AB, Cypralis Ltd, Everon Biosciences Inc, Faraday Pharmaceuticals, Gero Discovery, Glucox Biotech AB, Ischemix Inc, Lee's Pharmaceutical Holdings Ltd , LG Chem Ltd, Limulus Therapeutics Pty Ltd, MallInckrodt Plc, New Beta Innovation Limited, Nour Heart Therapeutics LLC, Pfizer Inc, Pharming Group NV, Proteo Inc, Radikal Therapeutics Inc, Reata Pharmaceuticals Inc, Revive Therapeutics Ltd, SBI Pharmaceuticals Co Ltd, Stealth BioTherapeutics Corp, TheraSource LLC, United Therapeutics Corp, Young Therapeutics LLC

REASONS TO BUY

• The current market conditions are forcing companies and investors worldwide to prioritize their investments and accelerate pipeline candidates only through careful quantitative assessment.
• This research work assists decision makers in pharmaceutical companies towards successful pipeline development through critically evaluated pipeline data
• Buyers can identify most promising drug candidates for treatment of Ischemia Reperfusion Injury
• It allows users to strengthen their pipeline through acquisitions, licensing and collaborations
• Users can estimate possible delays in the delivery of pipeline or launch of new products
• Stay ahead of competition through understanding their pipeline progression, strategies and outlook
• The report details all the pipeline candidates under investigation in various stages of development from Phase I through to Phase III to enable business development managers to understand the impact of new launches.
• Optimize your licensing and technology transfer strategies through identification of prospect partners

Contents

1. INTRODUCTION TO ISCHEMIA REPERFUSION INJURY

1.1 Ischemia Reperfusion Injury- Disease overview
1.2 Ischemia Reperfusion Injury- Market Size
1.3 Ischemia Reperfusion Injury- Companies Involved

2. ISCHEMIA REPERFUSION INJURY PIPELINE SNAPSHOT- 2020

2.1 Ischemia Reperfusion Injury Pipeline by Phase
2.2 Ischemia Reperfusion Injury Pipeline by Mechanism of Action
2.3 Ischemia Reperfusion Injury Pipeline by Route of Administration
2.4 Ischemia Reperfusion Injury Pipeline- New Molecular Entities
2.5 Ischemia Reperfusion Injury Pipeline- Orphan Drug Designation/ Special Designation

3. ISCHEMIA REPERFUSION INJURY DRUG PROFILES

3.1 Current Status
3.2 Ischemia Reperfusion Injury Drug Snapshot
3.3 Ischemia Reperfusion Injury Therapeutic Candidates- Originator/Licensor
3.4 Route of Administration
3.5 Mechanism of Action
3.6 NME
4.1 Acelerox LLC Ischemia Reperfusion Injury Pipeline Insights and Clinical Trials
4.2 Affinicon ApS Ischemia Reperfusion Injury Pipeline Insights and Clinical Trials
4.3 Amyndas Pharmaceuticals LLC Ischemia Reperfusion Injury Pipeline Insights and Clinical Trials
4.4 Apollo Therapeutics LLC Ischemia Reperfusion Injury Pipeline Insights and Clinical Trials
4.5 Aptorum Group Ltd Ischemia Reperfusion Injury Pipeline Insights and Clinical Trials
4.6 Argenx SE Ischemia Reperfusion Injury Pipeline Insights and Clinical Trials
4.7 Armaron Bio Pty Ltd Ischemia Reperfusion Injury Pipeline Insights and Clinical Trials
4.8 Axolo Pharma Inc Ischemia Reperfusion Injury Pipeline Insights and Clinical Trials
4.9 Balmes Transplantation SAS Ischemia Reperfusion Injury Pipeline Insights and Clinical Trials
4.10 Bolder Biotechnology Inc Ischemia Reperfusion Injury Pipeline Insights and Clinical Trials
4.11 Catalyst Biosciences Inc Ischemia Reperfusion Injury Pipeline Insights and Clinical Trials
4.12 Celdara Medical LLC Ischemia Reperfusion Injury Pipeline Insights and Clinical Trials
4.13 Cellmid Ltd Ischemia Reperfusion Injury Pipeline Insights and Clinical Trials
4.14 CFM Pharma Holding BV Ischemia Reperfusion Injury Pipeline Insights and Clinical Trials
4.15 Corline Biomedical AB Ischemia Reperfusion Injury Pipeline Insights and Clinical Trials
4.16 Cypralis Ltd Ischemia Reperfusion Injury Pipeline Insights and Clinical Trials
4.17 Everon Biosciences Inc Ischemia Reperfusion Injury Pipeline Insights and Clinical Trials
4.18 Faraday Pharmaceuticals Ischemia Reperfusion Injury Pipeline Insights and Clinical Trials
4.19 Gero Discovery Ischemia Reperfusion Injury Pipeline Insights and Clinical Trials
4.20 Glucox Biotech AB Ischemia Reperfusion Injury Pipeline Insights and Clinical Trials
4.21 Ischemix Inc Ischemia Reperfusion Injury Pipeline Insights and Clinical Trials
4.22 Lee's Pharmaceutical Holdings Ltd Ischemia Reperfusion Injury Pipeline Insights and Clinical Trials
4.23 LG Chem Ltd Ischemia Reperfusion Injury Pipeline Insights and Clinical Trials
4.24 Limulus Therapeutics Pty Ltd Ischemia Reperfusion Injury Pipeline Insights and Clinical Trials
4.25 MallInckrodt Plc Ischemia Reperfusion Injury Pipeline Insights and Clinical Trials
4.26 New Beta Innovation Limited Ischemia Reperfusion Injury Pipeline Insights and Clinical Trials
4.27 Nour Heart Therapeutics LLC Ischemia Reperfusion Injury Pipeline Insights and Clinical Trials
4.28 Pfizer Inc Ischemia Reperfusion Injury Pipeline Insights and Clinical Trials
4.29 Pharming Group NV Ischemia Reperfusion Injury Pipeline Insights and Clinical Trials
4.30 Proteo Inc Ischemia Reperfusion Injury Pipeline Insights and Clinical Trials
4.31 Radikal Therapeutics Inc Ischemia Reperfusion Injury Pipeline Insights and Clinical Trials
4.32 Reata Pharmaceuticals Inc Ischemia Reperfusion Injury Pipeline Insights and Clinical Trials
4.33 Revive Therapeutics Ltd Ischemia Reperfusion Injury Pipeline Insights and Clinical Trials
4.34 SBI Pharmaceuticals Co Ltd Ischemia Reperfusion Injury Pipeline Insights and Clinical Trials
4.35 Stealth BioTherapeutics Corp Ischemia Reperfusion Injury Pipeline Insights and Clinical Trials
4.36 TheraSource LLC Ischemia Reperfusion Injury Pipeline Insights and Clinical Trials
4.37 United Therapeutics Corp Ischemia Reperfusion Injury Pipeline Insights and Clinical Trials
4.38 Young Therapeutics LLC Ischemia Reperfusion Injury Pipeline Insights and Clinical Trials

5. ISCHEMIA REPERFUSION INJURY MARKET NEWS AND UPDATES

6. APPENDIX

6.1 Sources and Methodology
6.2 Contact Information